Dotbee.ai

Analysis Ys Biopharma Co Ltd. (YS)

6/1/2024

Analysis Ys Biopharma Co Ltd. (YS)

Analysis of Ys Biopharma Co Ltd. (YS)

YS Biopharma Co Ltd. has been showing some volatility in its stock price recently. The Relative Strength Index (RSI) values have been fluctuating around the 50 level, indicating a balanced market sentiment. The Moving Average Convergence Divergence (MACD) indicator has been hovering around the zero line, suggesting a lack of strong trend in either direction.

The stock price has been moving within a range, with the price closing around 0.83500 on the most recent trading day. The stock has shown some resistance around the 1.0000 level in the past, which could be a key level to watch for potential breakouts or reversals.

Overall, YS Biopharma Co Ltd. appears to be in a consolidation phase, with no clear trend direction at the moment. Traders and investors may want to wait for more decisive signals before making any significant trading decisions.

Balance Sheet

These are balance sheets. Here are the conclusions:

1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.

Earnings

The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.

Main Statystic 🧠

The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.

In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 31, 2024. The company shows good returns on assets and equity.

In terms of stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has experienced a moderate change in its fifty-two week range.

Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with high price to book and price to sales ratios. The enterprise value to EBITDA and revenue ratios are also notable.

The stock price summary includes key metrics such as the 50-day and 200-day moving averages, as well as the fifty-two week low and high prices.

Lastly, the dividends and splits information shows the company's dividend dates, split history, and dividend yield metrics. The company has a consistent dividend payout and yield.

Income statement 💸

These are the revenues. Here are the conclusions:

1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the sales revenue has shown a consistent upward trend.
3. The company has managed to grow its top line consistently, indicating strong market demand for its products or services.
4. Increasing sales revenue can be a positive indicator of the company's overall financial health and growth potential.

Cash Flow 💶

This is the cash flow statement. Here are some conclusions we can draw from the data:

1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. The company has been utilizing stock-based compensation as part of its operations.
8. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.

Earnings estimate

Based on the analysts' estimates for future quarterly and annual earnings per share:

1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.

2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.

3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.

4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests further growth compared to the EPS of $6.10 in the current fiscal year.

Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for the company in both the short term and the long term.

Revenue estimate

Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:

1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.

2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.

3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.

4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.

These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.

Growth estimates

Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:

1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.

These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still expected to be healthy.

Price target

Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.

MACD of YS

This is not investment advice. Remember to verify the information provided here.

Get access to the full analysis

  • Over 35 000 indexes
  • CFD, Forex, Crypto and Stocks Exchange
  • Over 150 Indicators
  • Pattern and candle analysis
  • Support and resistance levels
  • Fundamental, technical and sentimental analysis
  • Power from AI
Web versionApp StoreGoogle Play

Contacts

Telephone number

+48 32 700 81 66

Email address

[email protected]

Company information

Honey Payment Group S.A. at Al. Aleje Jerozolimskie 65 / 79, 00-697 Warsaw, Poland, Register number KRS 0000335507, NIP 5252859204, REGON 388760204. Honey Payment Group is listed on the Warsaw Stock Exchange (WSE) under the ticker symbol HPG. Link